Sell or avoid positions; expect significant price volatility and reduced liquidity as the stock moves to OTC markets. Monitor for any potential reverse split or capital raise attempts to regain listing, but timeline appears closed. The recent March offerings suggest the company had limited options and still failed.
Price Chart
Executive Summary
Reviva Pharmaceuticals received a final delisting notice from Nasdaq due to failure to maintain the minimum $1.00 bid price. Trading will be suspended on May 14, 2026, and the stock will transition to the OTCQB Venture Market. The delisting severely reduces liquidity and institutional access, compounding distress signaled by recent dilutive offerings.
Key Facts
- Nasdaq Hearings Panel determined to delist common stock due to non-compliance with Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)).
- Trading on Nasdaq will be suspended as of open of trading on May 14, 2026.
- Common stock will be quoted on OTCQB Venture Market under symbol RVPH starting May 14, 2026.
- Company filed two 424B5 offerings in March 2026 (approximately 55-56 days prior), indicating recent capital raises that failed to regain compliance.
Financial Impact
No specific financial figures provided in the filing; delisting expected to materially impair access to capital and stock liquidity.
Risk Factors
- Further price decline due to loss of institutional investors and index inclusion.
- Penny stock classification and stricter broker requirements may reduce retail participation.
- OTC markets may have limited liquidity, causing wide bid-ask spreads and difficulty exiting positions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016538 |
| Document: 0001437749-26-016538-index.html | 0001437749-26-016538 |
| Document: 0001437749-26-016538.txt | 0001437749-26-016538 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Press Release | $0.3521 $0.3521 | · 0.00% | ▲ +1.75% | $0.5000 (+42.01%) |
Jul 10, 2026 12w ago | 25-NSE | $0.6200 $0.4775 | ▲ +22.98% | ▲ +25.40% | $0.5000 (+19.35%) |
May 13, 2026 20w ago | Press Release | $0.3900 $0.6839 | ▼ −75.36% | ▼ −76.22% | $0.5000 (−28.21%) |
May 13, 2026 20w ago | 8-K | $0.3521 $0.7600 | ▼ −115.85% | ▼ −116.46% | $0.5000 (−42.01%) |
Apr 15, 2026 24w ago | 8-K | $0.8900 $0.8000 | ▼ −10.11% | ▼ −16.16% | $0.5000 (−43.82%) |
Mar 30, 2026 26w ago | Press Release | $0.6600 $0.8800 | ▲ +33.33% | ▲ +20.74% | $0.5000 (−24.24%) |
Mar 19, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▼ −2.41% | ▲ +5.21% | $0.5000 (+39.76%) |
Mar 18, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▲ +2.41% | ▼ −5.21% | $0.5000 (−39.76%) |
Mar 5, 2026 30w ago | 8-K | $4.20 $0.7200 | ▼ −82.86% | ▼ −79.07% | $0.5000 (−88.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access